Constitutional epimutation, which is an aberration in gene expression due to an altered epigenotype that is widely distributed in normal tissues (albeit frequently mosaic), provides an alternative mechanism to genetic mutation for cancer predisposition. Observational studies in cancer-affected families have revealed intergenerational inheritance of constitutional epimutation, providing unique insights into the heritability of epigenetic traits in humans. In this Opinion article, the potential contribution of constitutional epimutation to the 'missing' causality and heritability of cancer is explored.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Eichler, E. E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11, 446–450 (2010).
Maher, B. Personal genomes: the case of the missing heritability. Nature 456, 18–21 (2008).
Petronis, A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 465, 721–727 (2010).
McCarthy, M. I. & Hirschhorn, J. N. Genome-wide association studies: potential next steps on a genetic journey. Hum. Mol. Genet. 17, R156–R165 (2008).
Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415–428 (2002).
Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983).
Feinberg, A. P. & Vogelstein, B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111, 47–54 (1983).
De Smet, C. et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl Acad. Sci. USA 93, 7149–7153 (1996).
Cho, B. et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 307, 52–63 (2003).
Gama-Sosa, M. A. et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11, 6883–6894 (1983).
Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).
Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768–775 (2011).
Greger, V., Passarge, E., Hopping, W., Messmer, E. & Horsthemke, B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83, 155–158 (1989).
Gonzalez-Zulueta, M. et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55, 4531–4535 (1995).
Graff, J. R. et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55, 5195–5199 (1995).
Cunningham, J. M. et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58, 3455–3460 (1998).
Veigl, M. L. et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl Acad. Sci. USA 95, 8698–8702 (1998).
Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808–811 (1997).
Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681–8686 (1999).
Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787–793 (2006).
Hinoue, T. et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22, 271–282 (2012).
Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599–612 (2012).
Esteller, M. et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10, 3001–3007 (2001).
Steenman, M. J. et al. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7, 433–439 (1994).
Goelz, S. E., Vogelstein, B., Hamilton, S. R. & Feinberg, A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228, 187–190 (1985).
Cui, H., Horon, I. L., Ohlsson, R., Hamilton, S. R. & Feinberg, A. P. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4, 1276–1280 (1998).
Fernando, W. C. et al. The CIMP phenotype in BRAF mutant serrated polyps from a prospective colonoscopy patient cohort. Gastroenterol. Res. Pract. 2014, 374926 (2014).
Hawkins, N. J. et al. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod. Pathol. 22, 1588–1599 (2009).
Wong, J. J., Hawkins, N. J., Ward, R. L. & Hitchins, M. P. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod. Pathol. 24, 396–411 (2011).
Cho, N. Y., Kim, J. H., Moon, K. C. & Kang, G. H. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 454, 17–23 (2009).
Cui, H. et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753–1755 (2003).
Ito, Y. et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum. Mol. Genet. 17, 2633–2643 (2008).
Pufulete, M. et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 124, 1240–1248 (2003).
Slaughter, D. P., Southwick, H. W. & Smejkal, W. 'Field cancerization' in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 6, 963–968 (1953).
Candiloro, I. L. & Dobrovic, A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev. Res. 2, 862–867 (2009).
Fuke, C. et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann. Hum. Genet. 68, 196–204 (2004).
Bjornsson, H. T. et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 299, 2877–2883 (2008).
Kwabi-Addo, B. et al. Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 13, 3796–3802 (2007).
Heyn, H. et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. Cell Rep. 7, 331–338 (2014).
Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633–641 (2013).
Rapkins, R. W. et al. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. http:/dx.doi.org/10.1093/neuonc/nov064, (2015).
Brennan, K. & Flanagan, J. M. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev. Res. 5, 1345–1357 (2012).
Huang, W. Y. et al. Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 21, 2014–2021 (2012).
Nan, H. et al. Pre-diagnostic leukocyte genomic DNA methylation and the risk of colorectal cancer in women. PLoS ONE 8, e59455 (2013).
Holliday, R. The inheritance of epigenetic defects. Science 238, 163–170 (1987).
Hitchins, M. P. & Ward, R. L. Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J. Med. Genet. 46, 793–802 (2009).
van Overveld, P. G. et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat. Genet. 35, 315–317 (2003).
Horsthemke, B. Epimutations in human disease. Curr. Top. Microbiol. Immunol. 310, 45–59 (2006).
Hesson, L. B., Hitchins, M. P. & Ward, R. L. Epimutations and cancer predisposition: importance and mechanisms. Curr. Opin. Genet. Dev. 20, 290–298 (2010).
Oey, H. & Whitelaw, E. On the meaning of the word 'epimutation'. Trends Genet. 30, 519–520 (2014).
Moulton, T. et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet. 7, 440–447 (1994).
Moulton, T. et al. Genomic imprinting and Wilms' tumor. Med. Pediatr. Oncol. 27, 476–483 (1996).
Engel, J. R. et al. Epigenotype-phenotype correlations in Beckwith–Wiedemann syndrome. J. Med. Genet. 37, 921–926 (2000).
DeBaun, M. R. et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith–Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet. 70, 604–611 (2002).
Cooper, W. N. et al. Molecular subtypes and phenotypic expression of Beckwith–Wiedemann syndrome. Eur. J. Hum. Genet. 13, 1025–1032 (2005).
Scott, R. H. et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat. Genet. 40, 1329–1334 (2008).
Cerrato, F. et al. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith–Wiedemann syndrome and Wilms' tumour. Hum. Mol. Genet. 17, 1427–1435 (2008).
Murrell, A. et al. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS ONE 3, e1849 (2008).
Ravenel, J. D. et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J. Natl Cancer Inst. 93, 1698–1703 (2001).
Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D. & Hitchins, M. P. Milestones of Lynch syndrome: 1895–2015. Nat. Rev. Cancer 15, 181–194 (2015).
Miyakura, Y. et al. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin. Gastroenterol. Hepatol. 2, 147–156 (2004).
Suter, C. M., Martin, D. I. & Ward, R. L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36, 497–501 (2004).
Hitchins, M. et al. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 129, 1392–1399 (2005).
Hitchins, M. P. et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 356, 697–705 (2007).
Gazzoli, I., Loda, M., Garber, J., Syngal, S. & Kolodner, R. D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62, 3925–3928 (2002).
Hitchins, M. P. The role of epigenetics in Lynch syndrome. Fam. Cancer 12, 189–205 (2013).
Goel, A. et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int. J. Cancer 128, 869–878 (2011).
Hitchins, M. P. & Lynch, H. T. Dawning of the epigenetic era in hereditary cancer. Clin. Genet. 85, 413–416 (2014).
Pineda, M. et al. MLH1 methylation screening is effective in identifying epimutation carriers. Eur. J. Hum. Genet. 20, 1256–1264 (2012).
van Roon, E. H. et al. Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 10, 180 (2010).
Pinheiro, H. et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum. Mol. Genet. 19, 943–952 (2010).
Snell, C., Krypuy, M., Wong, E. M., Loughrey, M. B. & Dobrovic, A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 10, R12 (2008).
Hansmann, T. et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum. Mol. Genet. 21, 4669–4679 (2012).
Galetzka, D. et al. Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer. Epigenetics 7, 47–54 (2012).
Wong, E. M. et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev. Res. 4, 23–33 (2011).
Wojdacz, T. K., Thestrup, B. B., Cold, S., Overgaard, J. & Hansen, L. L. No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol. 7, 1451–1455 (2011).
Sparago, A. et al. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith–Wiedemann syndrome. Nat. Genet. 36, 958–960 (2004).
Chan, T. L. et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38, 1178–1183 (2006).
Ligtenberg, M. J. et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet. 41, 112–117 (2009).
Kuiper, R. P. et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum. Mutat. 32, 407–414 (2011).
Kempers, M. J. et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 12, 49–55 (2011).
Lynch, H. T. et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am. J. Gastroenterol. 106, 1829–1836 (2011).
Hitchins, M. P. et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5′UTR. Cancer Cell 20, 200–213 (2011).
Kwok, C. T. et al. The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. Eur. J. Hum. Genet. 22, 617–624 (2014).
Morak, M. et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. J. Med. Genet. 48, 513–519 (2011).
Raval, A. et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879–890 (2007).
Hitchins, M. et al. Germline epimutations of APC are not associated with inherited colorectal polyposis. Gut 55, 586–587 (2006).
van Doorn, R., Zoutman, W. H. & Gruis, N. A. Absence of germline epimutation of the CDKN2A gene in familial melanoma. J. Invest. Dermatol. 129, 781–784 (2009).
Hyland, P. L. et al. Constitutional promoter methylation and risk of familial melanoma. Epigenetics 9, 685–692 (2014).
Nag, A. et al. Chromatin signature of widespread monoallelic expression. elLfe 2, e01256 (2013).
Cubas, P., Vincent, C. & Coen, E. An epigenetic mutation responsible for natural variation in floral symmetry. Nature 401, 157–161 (1999).
Manning, K. et al. A naturally occurring epigenetic mutation in a gene encoding an SBP-box transcription factor inhibits tomato fruit ripening. Nat. Genet. 38, 948–952 (2006).
Pal-Bhadra, M. et al. Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 303, 669–672 (2004).
Morgan, H. D., Sutherland, H. G., Martin, D. I. & Whitelaw, E. Epigenetic inheritance at the agouti locus in the mouse. Nat. Genet. 23, 314–318 (1999).
Rakyan, V. K. et al. Transgenerational inheritance of epigenetic states at the murine AxinFu allele occurs after maternal and paternal transmission. Proc. Natl Acad. Sci. USA 100, 2538–2543 (2003).
Feng, S., Jacobsen, S. E. & Reik, W. Epigenetic reprogramming in plant and animal development. Science 330, 622–627 (2010).
Heijmans, B. T. et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. USA 105, 17046–17049 (2008).
DeBaun, M. R., Niemitz, E. L. & Feinberg, A. P. Association of in vitro fertilization with Beckwith–Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am. J. Hum. Genet. 72, 156–160 (2003).
Hiura, H. et al. Characterization of DNA methylation errors in patients with imprinting disorders conceived by assisted reproduction technologies. Hum. Reprod. 27, 2541–2548 (2012).
Casati, L., Sendra, R., Sibilia, V. & Celotti, F. Endocrine disrupters: the new players able to affect the epigenome. Front. Cell Dev. Biol. http:/dx.doi.org/10.3389/fcell.2015.00037, (2015).
Xin, F., Susiarjo, M. & Bartolomei, M. S. Multigenerational and transgenerational effects of endocrine disrupting chemicals: a role for altered epigenetic regulation? Semin. Cell Dev. Biol. http:/dx.doi.org/10.1016/j.semcdb.2015.05.008, (2015).
Manikkam, M., Tracey, R., Guerrero-Bosagna, C. & Skinner, M. K. Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. PLoS ONE 7, e46249 (2012).
Manikkam, M., Haque, M. M., Guerrero-Bosagna, C., Nilsson, E. E. & Skinner, M. K. Pesticide methoxychlor promotes the epigenetic transgenerational inheritance of adult-onset disease through the female germline. PLoS ONE 9, e102091 (2014).
Iqbal, K. et al. Deleterious effects of endocrine disruptors are corrected in the mammalian germline by epigenome reprogramming. Genome Biol. 16, 59 (2015).
Bygren, L. O., Kaati, G. & Edvinsson, S. Longevity determined by paternal ancestors' nutrition during their slow growth period. Acta Biotheor 49, 53–59 (2001).
Kaati, G., Bygren, L. O. & Edvinsson, S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur. J. Hum. Genet. 10, 682–688 (2002).
Chen, T. H., Chiu, Y. H. & Boucher, B. J. Transgenerational effects of betel-quid chewing on the development of the metabolic syndrome in the Keelung Community-based Integrated Screening Program. Am. J. Clin. Nutr. 83, 688–692 (2006).
Kaati, G., Bygren, L. O., Pembrey, M. & Sjostrom, M. Transgenerational response to nutrition, early life circumstances and longevity. Eur. J. Hum. Genet. 15, 784–790 (2007).
Grossniklaus, U., Kelly, W. G., Ferguson-Smith, A. C., Pembrey, M. & Lindquist, S. Transgenerational epigenetic inheritance: how important is it? Nat. Rev. Genet. 14, 228–235 (2013).
Stoger, R., Kajimura, T. M., Brown, W. T. & Laird, C. D. Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum. Mol. Genet. 6, 1791–1801 (1997).
Hitchins, M. P. & Ward, R. L. Erasure of MLH1 methylation in spermatozoa-implications for epigenetic inheritance. Nat. Genet. 39, 1289 (2007).
Slatkin, M. Epigenetic inheritance and the missing heritability problem. Genetics 182, 845–850 (2009).
Furrow, R. E., Christiansen, F. B. & Feldman, M. W. Environment-sensitive epigenetics and the heritability of complex diseases. Genetics 189, 1377–1387 (2011).
Heyn, H. et al. DNA methylation contributes to natural human variation. Genome Res. 23, 1363–1372 (2013).
Smallwood, S. A. et al. Dynamic CpG island methylation landscape in oocytes and preimplantation embryos. Nat. Genet. 43, 811–814 (2011).
Santos, F., Hendrich, B., Reik, W. & Dean, W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev. Biol. 241, 172–182 (2002).
The author declares no competing financial interests.
- Cancer heritability
There are various measures of the heritability of cancer phenotypes. In general, it is measured as the relative risk ratio of disease in the relatives of affected patients versus the general population, or the concordance rates between monozygotic and dizygotic twins.
- Constitutional epimutations
Aberrant changes in gene expression owing to altered epigenotypes that are widespread in normal somatic tissues due to their origins in the gamete or early embryo.
- Constitutional epivariants
Epigenetic differences between members of the general population that may contribute to natural phenotypic variation among humans.
- Epigenetic marks
Refers to the molecular modifications to the primary DNA sequence. These include, but are not limited to, covalent modifications to cytosine, histone occupancy and variants, and histone tail moieties. This Opinion article primarily refers to 5-methylcytosine, which occurs mostly at CpG dinucleotides in mammals. Although RNA molecules are not considered epigenetic marks, they interact with epigenetic processes to bring about epigenetic change.
The mitotically stable pattern or type of DNA modification or modifications to the primary DNA sequence; for example, the presence or absence of CpG methylation and other accompanying modifications that regulate transcriptional activity. It may refer to the epigenetic state at a particular genetic locus or more generally across the genome.
An aberrant change in gene expression owing to an altered epigenotype.
- Index cases
The first case of a disease in a group (for example, a family or population) to be brought to clinical attention: that is, the first case to be identified with a novel causative defect.
- Intergenerational inheritance of epigenetic effects
The non-genetic transmission of a phenotypic trait from one generation to another due to a shared environmental, lifestyle or nutritional exposure. If the exposure occurs systemically in a pregnant female (F0), the fetus (F1) is also exposed, as are the gamete precursors (primordial germ cells) of the next generation of progeny (F2). To definitively distinguish transgenerational epigenetic inheritance from the intergenerational inheritance of epigenetic effects, the trait would need to be observed in the F3 generation.
The cancer-affected member of a family who first sought medical attention and via whom the family was ascertained for genetic or epigenetic study.
- Somatic epitypes
Types of epigenotypes that are acquired in somatic cells during the lifetime of an individual in response to environmental influences.
- Transgenerational epigenetic inheritance
The transmission of an epigenetic state (a particular epigenotype) from parent to offspring via the gametes, independently of genetics. Transgenerational epigenetic inheritance does not necessitate that the epigenotype is conveyed through the gamete with its somatic epigenetic modifications intact (for example, in a hypermethylated state). This definition has been extended to include alternative forms of epigenetic signals (other than methylation) that convey a memory of the former parental somatic state via the gamete to become fully reinstated in the progeny. The molecular basis for transgenerational epigenetic inheritance remains unknown, although the transfer of epigenetic modifying RNA species via the gametes provides one possible unifying mechanism across species.
- Vertical inheritance
Transmission of a trait (genetic, epigenetic or phenotypic) from parent to offspring.
About this article
Cite this article
Hitchins, M. Constitutional epimutation as a mechanism for cancer causality and heritability?. Nat Rev Cancer 15, 625–634 (2015). https://doi.org/10.1038/nrc4001
PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations
Clinical Epigenetics (2021)
Application of targeted nanopore sequencing for the screening and determination of structural variants in patients with Lynch syndrome
Journal of Human Genetics (2021)
Clinical Epigenetics (2020)
Clinical Epigenetics (2020)
Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation
Clinical Epigenetics (2019)